Core Viewpoint - Rosen Law Firm is reminding investors who purchased Krispy Kreme, Inc. securities between February 25, 2025, and May 7, 2025, of the July 15, 2025, deadline to serve as lead plaintiff in a class action lawsuit [1] Group 1: Class Action Details - A class action lawsuit has been filed against Krispy Kreme, and investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1][2] - Investors wishing to serve as lead plaintiff must file with the court by July 15, 2025 [2] Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest settlement against a Chinese company at the time and being ranked No. 1 for securities class action settlements in 2017 [3] - The firm has recovered hundreds of millions of dollars for investors, securing over $438 million in 2019 alone [3] Group 3: Case Allegations - The lawsuit alleges that during the class period, Krispy Kreme made false and misleading statements regarding the demand for its products at McDonald's locations, which declined materially after the initial marketing launch [4] - It is claimed that the partnership with McDonald's was not profitable, leading to a pause in expansion into new locations and that the positive statements made by the defendants were materially misleading [4]

Group 1 - The Rosen Law Firm is reminding purchasers of American Depositary Shares (ADSs) of Reckitt Benckiser Group PLC about the lead plaintiff deadline of August 4, 2025, for a class action lawsuit [1] - Investors who purchased Reckitt ADSs may be entitled to compensation through a contingency fee arrangement, meaning no out-of-pocket fees or costs [2] - A class action lawsuit has already been filed, and interested parties can join by contacting the Rosen Law Firm [3][6] Group 2 - The lawsuit alleges that during the class period, Reckitt failed to warn investors that preterm infants were at increased risk of developing necrotizing enterocolitis (NEC) from consuming its Enfamil formula, which misled investors about the company's business prospects [5]

NEW YORK, June 17, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Red Cat Holdings, Inc. (NASDAQ: RCAT) between March 18, 2022 and January 15, 2025, both dates inclusive (the “Class Period”), of the important July 22, 2025 lead plaintiff deadline. SO WHAT: If you purchased Red Cat securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased securities of Iovance Biotherapeutics, Inc. during the specified Class Period of the upcoming lead plaintiff deadline on July 14, 2025, for a class action lawsuit [1][2]. Group 1: Class Action Details - The class action lawsuit claims that during the Class Period, Iovance made false and misleading statements regarding the effectiveness of new Authorized Treatment Centers (ATCs) in treating patients with Amtagvi, leading to higher costs and lower revenue [3]. - The lawsuit alleges that the delays in treatment timelines and ineffective patient identification by Iovance's sales team resulted in increased patient drop-offs, which negatively impacted the company's financial performance [3]. Group 2: Legal Representation - Investors are encouraged to select qualified legal counsel with a proven track record in securities class actions, as many firms may not have the necessary experience or resources [4]. - The Rosen Law Firm has a history of successful settlements in securities class actions, having recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Bitfarms Ltd. securities during the specified Class Period of the upcoming lead plaintiff deadline on July 8, 2025, for a class action lawsuit [1][2]. Group 1: Class Action Details - Investors who bought Bitfarms securities between March 21, 2023, and December 9, 2024, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by the July 8, 2025 deadline [2][4]. - The lawsuit alleges that Bitfarms made false and misleading statements regarding its financial reporting and internal controls, leading to potential misstatements in financial statements that may require restatement [4]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company at the time and being ranked No. 1 for the number of settlements in 2017 [3]. - The firm has recovered hundreds of millions of dollars for investors, securing over $438 million in 2019 alone [3]. - Founding partner Laurence Rosen was recognized as a Titan of Plaintiffs' Bar by Law360 in 2020, and many attorneys at the firm have received accolades from Lawdragon and Super Lawyers [3].

Core Viewpoint - A class action lawsuit has been filed against Rocket Pharmaceuticals, Inc. for allegedly providing misleading information regarding the safety and clinical trial protocol of its product RP-A501, leading to inflated stock prices and subsequent investor losses [1][5]. Group 1: Lawsuit Details - The class action lawsuit is on behalf of purchasers of Rocket Pharmaceuticals securities between February 27, 2025, and May 26, 2025 [1]. - The lawsuit claims that Rocket Pharmaceuticals made overwhelmingly positive statements while concealing material adverse facts about the safety of RP-A501, including the risk of Serious Adverse Events (SAEs) [5]. - The company allegedly amended the trial protocol without informing shareholders, which contributed to artificially inflated stock prices [5]. Group 2: Investor Information - Investors who purchased securities during the class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - Interested investors can join the class action by visiting the provided link or contacting the law firm directly [3][6]. - A lead plaintiff must be appointed by August 11, 2025, to represent the class in the lawsuit [1][3]. Group 3: Law Firm Credentials - The Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time [4]. - The firm has consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions of dollars for investors [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Fortrea Holdings, Inc. securities during the specified class period of the upcoming lead plaintiff deadline on August 1, 2025, and the potential for compensation without out-of-pocket costs [1][2]. Group 1: Class Action Details - The class action lawsuit has been filed against Fortrea Holdings, alleging that the company made false and misleading statements regarding its revenue projections and cost savings, which inflated its EBITDA targets for 2025 [4]. - Investors who purchased Fortrea securities between July 3, 2023, and February 28, 2025, may be eligible for compensation [1][4]. - A lead plaintiff must file a motion with the court by August 1, 2025, to represent other class members in the litigation [2]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest settlement against a Chinese company at the time and being ranked No. 1 for securities class action settlements in 2017 [3]. - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [3]. - Founding partner Laurence Rosen was recognized as a Titan of Plaintiffs' Bar by Law360 in 2020, highlighting the firm's expertise in this area [3].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Organon & Co. securities during the specified class period of the upcoming lead plaintiff deadline for a class action lawsuit [1][2]. Group 1: Class Action Details - The class period for the Organon securities lawsuit is from October 31, 2024, to April 30, 2025, inclusive [1]. - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A lead plaintiff must file a motion with the court by July 22, 2025, to represent other class members [2]. Group 2: Legal Representation - Investors are encouraged to select qualified legal counsel with a proven track record in securities class actions [3]. - Rosen Law Firm has a history of significant settlements, including the largest securities class action settlement against a Chinese company at the time [3]. - The firm has consistently ranked in the top 4 for securities class action settlements since 2013 and recovered hundreds of millions for investors [3]. Group 3: Case Allegations - The lawsuit alleges that Organon's defendants made misleading statements about the company's priorities, particularly regarding capital allocation and dividend payments [4]. - It is claimed that the defendants concealed the importance of debt reduction following the acquisition of Dermavant, leading to a 70% decrease in the regular quarterly dividend [4]. - The lawsuit asserts that investors suffered damages when the true information was revealed [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Avis Budget Group, Inc. securities during the specified Class Period of the upcoming lead plaintiff deadline on June 24, 2025 [1]. Group 1: Class Action Details - Investors who purchased Avis Budget securities between February 16, 2024, and February 10, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by submitting a form or contacting the law firm [3][6]. - The lead plaintiff must file a motion with the Court by June 24, 2025, to represent other class members in the litigation [3]. Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions, highlighting its own achievements in this area [4]. - The firm has secured significant settlements for investors, including over $438 million in 2019 alone, and has been consistently ranked among the top firms for securities class action settlements [4]. Group 3: Case Allegations - The lawsuit alleges that during the Class Period, Avis Budget made false and misleading statements regarding its fleet rotation plan, which negatively impacted the value of its vehicles and led to billions in impairment charges [5]. - The claims suggest that these misstatements resulted in significant financial losses for investors when the true situation was revealed [5].

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of investors who purchased PepGen Inc. securities between March 7, 2024, and March 3, 2025, due to alleged misleading statements regarding the effectiveness and safety of PGN-EDO51 and the CONNECT2 study [1][5]. Group 1: Lawsuit Details - The class action lawsuit claims that PepGen made false and misleading statements about PGN-EDO51's effectiveness and safety, the CONNECT2 study's adequacy for FDA approval, and the overall clinical and commercial prospects of PGN-EDO51 [5]. - Investors who purchased PepGen securities during the class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. Group 2: Next Steps for Investors - Investors interested in joining the class action can do so by visiting the provided link or contacting the law firm directly [3][6]. - A lead plaintiff must be appointed by August 8, 2025, to represent the class in the lawsuit [1][3]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time [4]. - The firm has consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions of dollars for investors [4].